Texas Capital Bancshares Inc
Change company Symbol lookup
Select an option...
TCBI Texas Capital Bancshares Inc
IBB iShares Nasdaq Biotechnology ETF
NEP Nextera Energy Partners LP
FRAN Francesca's Holdings Corp
CDTI CDTi Advanced Materials Inc
UBER Uber Technologies Inc
MTX Minerals Technologies Inc
PRGS Progress Software Corp
CODA Coda Octopus Group Inc
WAB Westinghouse Air Brake Technologies Corp
Go

Financials : Banks | Small Cap Growth
Company profile

Texas Capital Bancshares, Inc. is a bank holding and a financial holding company. The Company is the parent of Texas Capital Bank, National Association (the Bank). It offers a range of loan, deposit account and other financial products and services to its customers. It offers a range of products and services for its business customers, including commercial loans for general corporate purposes, including financing for working capital, internal growth, acquisitions and financing for business insurance premiums; medium- and long-term tax-exempt loans for municipalities and other governmental and tax-exempt entities; wealth management and trust services, and letters of credit. It also provides banking services for its individual customers, including personal wealth management and trust services; certificates of deposit; interest-bearing and non-interest-bearing checking accounts; traditional money market and savings accounts; loans, both secured and unsecured, and Internet banking.

Postmarket

Last Trade
Delayed
$38.75
0.23 (0.60%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$38.52
Day's Change
1.21 (3.24%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
38.84
Day's Low
37.15
Volume
(Heavy Day)
Volume:
464,851

10-day average volume:
341,646
464,851

Sarepta shares fall on potential regulatory delay for experimental Duchenne drug

7:38 am ET September 10, 2020 (MarketWatch)
Print

Shares of Sarepta Therapeutics Inc. (SRPT) were down 0.7% in premarket trading on Thursday, the day after the company said it had submitted a written response to the Food and Drug Administration for its investigational Duchenne muscular dystrophy treatment. The regulator had asked Sarepta to use an additional assay before patients are dosed in the trials. Analysts say the regulatory request will slow down Sarepta's timeline for seeking approval for its gene therapy, with some saying the lag time for the initiation of the Phase 3 trial could give a competitive boost to Pfizer Inc. (PFE) experimental DMD therapy, according to Raymond James analyst Danielle Brill. "We don't think Sarepta will have trouble getting through this; and we expect just a limited delay," Bernstein's Vincent Chen wrote in a note to investors on Thursday. "Our sense is Sarepta has plenty of options for potential potency release assays; it's just a matter of aligning with the FDA, and validating the assays." Sarepta's stock is up 1.1% so far this year, while the S&P 500 has gained 5.2%.

-Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

September 10, 2020 07:38 ET (11:38 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.